GEA
IOVA icon

Glen Eagle Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Glen Eagle Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$3.29K – 995
2020
Q3 		$3.29K Hold
100
– – ﹤0.01% 744
2020
Q2 		$2.75K Hold
100
– – ﹤0.01% 733
2020
Q1 		$2.99K Hold
100
– – ﹤0.01% 683
2019
Q4 		$2.77K Hold
100
– – ﹤0.01% 760
2019
Q3 		$1.82K Hold
100
– – ﹤0.01% 715
2019
Q2 		$2.45K Buy
+100
New +$1.51K ﹤0.01% 679

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Glen Eagle Advisors's IOVA Position: Q4 2020 in Review

Glen Eagle Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2020, closing a stake of 100 shares — an estimated $3.29K sold.

Glen Eagle Advisors first reported a position in IOVA in Q2 2019 and held it in 6 quarters. The position peaked at $3.29K in Q3 2020. 269 funds tracked by Wall St. Rank hold IOVA as of Q4 2020.

  • Glen Eagle Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Glen Eagle Advisors sold 100 Iovance Biotherapeutics shares in Q4 2020, an estimated $3.29K.
  • Glen Eagle Advisors first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 6 quarters.
  • Glen Eagle Advisors's Iovance Biotherapeutics position peaked at $3.29K in Q3 2020.
  • 269 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2020.

Based on Glen Eagle Advisors's 13F filing for Q4 2020, filed 13 Aug 2024.